Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $60.67 (market cap $3.39B), while Vertex Pharmaceuticals Incorporated trades at $508.18 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 37.6× SP Funds S&P 500 Sharia Industry Exclusions ETF's market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SP Funds S&P 500 Sharia Industry Exclusions ETF for 64 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SPUS | VRTX | |
|---|---|---|
Market Cap | $3.39B | $127.55B |
Volume | 349,184 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $61.15 | $557.96 |
52-Week Low | $46.65 | $407.37 |
Typical Hold Time | 64 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPUS (SP Funds S&P 500 Sharia Industry Exclusions ETF) trades at $61.07, down 0.13% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows consistent dividend payments of $0.03 monthly through mid-2026. Short interest surged 174.5% to 257,142 shares in September 2026, indicating growing bearish sentiment among some investors despite the overall technical strength.
The ETF's outlook remains mixed with strong technical momentum countered by elevated short interest and overbought RSI levels. Investment opportunity lies in Sharia-compliant S&P 500 exposure, while risks include concentrated short positioning and potential mean reversion from current technical extremes.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
